Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Genmab (Otc) ($GMAB) announced an update on their ongoing clinical study. Genmab has announced a new Phase 2 clinical study designed to evaluate ...

July 7, 2025 – The FDA has granted quick approval to a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC). The drug, called sunvozertinib and sold as Zegfrovy ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final ...

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events than standard therapy.

The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, locally advanced, or metastatic non-squamous non-small cell lung cancer ...

Johnson & Johnson currently boasts one of the largest lineups of multiple myeloma products. Since its first FDA approval of a drug for this type of blood cancer a decade ago, the pharmaceutical giant ...

June 12, 2025 – The FDA has approved a first-of-its-kind oral pill to treat a rare type of advanced lung cancer that often spreads to the brain. The new drug, known as taletrectinib but sold as ...